Summer 2026

Legal and Compliance Intern

Posted on 9/25/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$30 - $32/hr

Princeton, NJ, USA

Hybrid

Hybrid role; minimum two days in-office per week; must be within commuting distance of Princeton, NJ.

US Citizenship Required

Category
Legal & Compliance (2)
,
Requirements
  • This position requires candidates to have completed the first or second year of a full-time Law Degree program
  • A demonstrated interest in pharma/life sciences, healthcare law, policies and legislation
  • Ability to use technology to modernize our ways of working
  • Strong written and verbal communication skills
  • Interns are required to be able to work from May 26, 2026 to August 19, 2026
  • The ability to work a hybrid schedule is required
  • Candidates are required to live within a commutable distance of Princeton, NJ
  • This position requires that candidates be able to work in the United States on a permanent and on-going basis
Responsibilities
  • Working closely with the Legal and Compliance teams on assigned tasks and working on projects which may include, but is not limited to, the following:
  • Assisting with the implementation of electronic contracts management system and various phases of contract workflow
  • Reconciling contract assignments in connection with licensed assets
  • Conducting Legal research on various issues affecting life science companies; this may include trends in enforcement, fraud and abuse, evolving digital legal issues, patient engagement and advocacy, commercial issues, and legislative developments
  • Assisting with the assessment of state and federal privacy laws and regulations to help support the advancement of the KKNA privacy program
  • Supporting the Company’s HR function through the evaluation and enforcement of state and federal labor and employment laws
  • Helping synthesize important Legal advice and guidance provided to commercial functions in a format suitable for internal department knowledge sharing. For example, building a reference guide or slide deck
  • Learning about our therapeutic areas and products and spending time shadowing Attorneys and Compliance Officers at appropriate meetings
  • Advancing slide libraries of current enforcement activity and trends
  • Engaging in live Compliance monitoring (e.g., virtual speaker program)
  • Collecting and analyzing data related to field-based activities
  • Assisting in the creation and/or updating of Compliance training, which include various formats: slide decks, modules, and micro-trainings
  • Assisting in the creation and/or updating of Legal policies and procedures
  • Drafting and/or updating Compliance policies, guidelines, forms, and communications
  • Supporting the Enterprise Risk Management team with risk assessment and reporting processes
  • Helping to create and maintain a culture of compliance within the company
  • Completing ad hoc and special Legal and Compliance projects as they arise

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kyowa Kirin who can refer or advise you

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE